Durvalumab + Acalabrutinib
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Central Nervous System Lymphoma
Conditions
Primary Central Nervous System Lymphoma
Trial Timeline
Apr 29, 2021 → May 31, 2028
NCT ID
NCT04462328About Durvalumab + Acalabrutinib
Durvalumab + Acalabrutinib is a phase 1 stage product being developed by AstraZeneca for Primary Central Nervous System Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT04462328. Target conditions include Primary Central Nervous System Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04462328 | Phase 1 | Active |
Competing Products
20 competing products in Primary Central Nervous System Lymphoma